Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

20042,835 citationsJournal Article

Authors

Stephanos J. Hadziyannis · University of Göttingen

Hoel Sette · Universitätsmedizin Göttingen

Timothy R. Morgan · Universitätsmedizin Göttingen

Vijayan Balan · Universitätsmedizin Göttingen

Moises Diago · Universitätsmedizin Göttingen

Patrick Marcellin · Universitätsmedizin Göttingen

Giuliano Ramadori · Universitätsmedizin Göttingen

Henry Bodenheimer

Abstract

Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.

Topics & Keywords

Hepatitis C virus research Liver Disease Diagnosis and Treatment Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Internal Medicine

Volume 140, Issue 5, pp. 346-355

DOI: 10.7326/0003-4819-140-5-200403020-00010

Field-Weighted Citation Impact: 115.46